| Name | Title | Contact Details |
|---|---|---|
Deshanand Singh |
Chief Technology Officer | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Inmata Solutions is a Fremont, CA-based company in the Software and Internet sector.
Single Touch Systems Inc. is an innovative mobile solutions provider serving retailers, advertisers and brands. Through patented technologies and a modular, adaptable platform, SITO’s multi-channel messaging gateway enables marketers to reach consumers on all types of connected devices, with information that engages interest, drives transactions and strengthens relationships and loyalty.
Athena Software is a Kitchener, ON-based company in the Software and Internet sector.